Navigating AI Act Implementation Challenges in MedTech

By HEOR Staff Writer

August 5, 2025

MedTech Europe recently marked the first anniversary of the EU Artificial Intelligence Act (AI Act). It highlights challenges in implementing the AI Act, such as regulatory overlap with the Medical Devices Regulation (MDR)/IVDR frameworks. This overlap could delay patient access to innovative medical technologies. The organization calls for clearer exemptions for clinical investigations and performance studies under the AI Act. Aligned implementation is needed to foster AI-driven advancements in diagnostics and treatment.

Key Insights

The AI Act’s post-implementation phase risks creating conflicting obligations for manufacturers of high-risk AI systems in medical devices. Overlapping requirements between MDR/IVDR and the AI Act complicate compliance. MedTech Europe stresses the need for legal clarity to prevent regulatory bottlenecks, especially for clinical studies. These studies are critical for developing safe and effective technologies. Other challenges include data quality, interoperability, and resource disparities across EU member states. Targeted support is also needed for under-resourced regions.

The AI Act entered into force on August 1, 2024, and high-risk AI systems in medical devices must comply by August 2027. Existing regulations like MDR/IVDR already govern medical AI tools but lack alignment with the AI Act’s requirements. Challenges persist in data infrastructure and clinical workflow integration. Germany, for example, struggles with fragmented health data and insufficient public health AI applications.

Implications

Overlapping regulations could escalate administrative burdens for manufacturers. This might delay the deployment of AI-driven diagnostic tools and worsen health disparities. Prolonged compliance processes could increase costs and slow innovation. Effective implementation, however, could enhance safety and interoperability. Harmonized oversight by the European AI Office is crucial, and aligning AI Act requirements with MDR/IVDR would help maintain Europe’s position as a hub for medical AI innovation.

For further insights, explore MedTech Europe’s article here.

Reference url

Recent Posts

Global Growth and Challenges in Pharmacy Vaccination Training

By João L. Carapinha

May 13, 2026

Pharmacy Vaccination Training has expanded rapidly worldwide, with the number of countries offering pharmacist vaccination programs rising from 12 in 2016 to 64 by 2024. This 433 percent growth means training is now available in every nation where pharmacists may administer vaccines, including pr...
Key Strategies in Neonatal Infection Management: Insights from NICE Guideline NG195
The NICE guideline NG195 establishes a structured framework for neonatal infection management in newborns up to 28 days corrected gestational age, treating at-risk pregnant individuals, and managing suspected or confirmed infections in neonates. It emphasizes timely recognition to avoid delays, j...
Merck Oncology Advancements Highlight Long-Term Data and Pipeline Progress at ASCO 2026
Merck oncology advancements continue to deliver meaningful progress for patients. New long-term data from multiple trials highlight sustained survival benefits across lung cancer, breast cancer, melanoma, and other tumor types. These advancements will feature prominently at the 2026 American S...